Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs AMIKIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of superficial ocular infections caused by susceptible organisms,Reduction of inflammation in corticosteroid-responsive ocular conditions,Off-label: treatment of otitis externa (otic preparations)
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Bacitracin: not metabolized, excreted renally; neomycin: minimally metabolized, excreted renally; polymyxin B: metabolism unknown, excreted renally; hydrocortisone acetate: hepatic metabolism via CYP3A4, glucuronidation, sulfation.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Bacitracin: ~10% (albumin). Neomycin: <30% (albumin). Polymyxin B: 55-60% (albumin, alpha-1-acid glycoprotein). Hydrocortisone acetate: 90-95% (corticosteroid-binding globulin, albumin).
0-10% (low binding to albumin).
Bacitracin: 0.3 L/kg (minimal distribution). Neomycin: 0.2-0.4 L/kg (extracellular fluid). Polymyxin B: 0.6-0.8 L/kg (extensively bound to cell membranes). Hydrocortisone acetate: 0.3-0.6 L/kg (total body water).
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
Topical/otic/ophthalmic: negligible systemic absorption (<1% for bacitracin, neomycin, polymyxin B; <5% for hydrocortisone acetate). Oral: not applicable (not administered systemically).
IM: 100% (complete absorption); oral: <1% (not absorbed).
No systemic absorption anticipated with topical, ophthalmic, or otic use; however, for extensive topical application, caution in renal impairment due to neomycin and polymyxin B. GFR <30 m L/min: monitor for nephrotoxicity; reduce frequency if topical use over large areas.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
No specific adjustment required for topical, ophthalmic, or otic use. Hydrocortisone acetate is hepatically metabolized; however, systemic exposure is minimal. Child-Pugh Class C: use with caution if applied to large areas or broken skin.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
Children: Apply a thin layer to affected area 3-4 times daily. Ophthalmic: Use same as adult dose. Otic: Infants and children: 3 drops into affected ear(s) 3-4 times daily. Safety and efficacy in neonates not established.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
No specific dose adjustment required. Use with caution in elderly with impaired renal or hepatic function, especially if applied to large areas. Monitor for skin atrophy and systemic effects of hydrocortisone with prolonged use.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
None.
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
Prolonged use may lead to secondary infections (e.g., fungal) or hypersensitivity; ophthalmic use may cause increased intraocular pressure, cataract formation, and delayed wound healing; avoid use in patients with epithelial herpes simplex keratitis; systemic absorption may cause nephrotoxicity and ototoxicity (especially neomycin); use with caution in hepatic impairment.
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
Hypersensitivity to any component; ocular tuberculosis, viral infections of the cornea (e.g., herpes simplex keratitis), fungal diseases of the eye; untreated purulent infections; use in ears with tympanic membrane perforation (otic preparations).
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
No significant food interactions. No dietary restrictions required.
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone acetate when used topically. Avoid prolonged use of high-dose hydrocortisone during first trimester due to potential corticosteroid effects.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
Systemic absorption is minimal; topical application likely poses low risk to nursing infant. M/P ratio not established for the combination. Avoid application to breast area to prevent infant ingestion.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
No dose adjustment required for topical application during pregnancy. Use sparingly on limited areas to minimize systemic absorption.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
This combination product is used for otitis externa and certain ophthalmic infections. The hydrocortisone reduces inflammation, but can mask signs of fungal or viral superinfection. Avoid use in patients with tympanic membrane perforation due to risk of ototoxicity from neomycin and polymyxin B. Neomycin carries sensitization risk; prolonged use may cause contact dermatitis. Monitor for overgrowth of non-susceptible organisms when used beyond 10 days.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
Use exactly as prescribed; do not exceed recommended duration.,Avoid contact with eyes unless specifically directed for ophthalmic use.,Do not use if you have a perforated eardrum or ear discharge.,Stop use and notify your doctor if symptoms worsen or persist after 10 days.,Inform your doctor if you experience new pain, redness, or swelling.,Keep this medication out of reach of children.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs AMIKIN, answered by our medical review team.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.. AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE and AMIKIN depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is: Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.. The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE and AMIKIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is classified as Category A/B. Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone a. AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.